Acrivon Therapeutics, Inc. Payments to Acquire Debt Securities, Available-for-sale
Acrivon Therapeutics, Inc. (ACRV) reported Payments to Acquire Debt Securities, Available-for-sale of $26.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-12
- Acrivon Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $9.97M, a 33.81% decline year-over-year.
- Acrivon Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $16.86M, a 16.66% decline year-over-year.
- Acrivon Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $13.26M, a 61.86% decline year-over-year.
- Acrivon Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $33.19M, a 564.07% increase year-over-year.
- Acrivon Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $81.73M, a 59.72% decline from fiscal 2024.
- Acrivon Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $202.93M, a 258.98% increase from fiscal 2023.
- Acrivon Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $56.53M, a 62.36% decline from fiscal 2022.
- Acrivon Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $150.18M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $26.82M 10-Q · filed 2026-08-12 | $40.08M derived: sum of 3 quarters · filed 2026-08-12 | $73.27M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $16.86M 10-Q · filed 2026-05-13 | $30.12M derived: sum of 2 quarters · filed 2026-05-13 | $63.31M derived: sum of 3 quarters · filed 2026-05-13 | $78.36M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $13.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $46.45M derived: sum of 2 quarters · filed 2026-03-19 | $61.50M derived: sum of 3 quarters · filed 2026-08-12 | $81.73M 10-K · filed 2026-03-19 |
| 2025-09-30 | $33.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $48.25M derived: sum of 2 quarters · filed 2026-08-12 | $68.47M 10-Q · filed 2025-11-13 | $103.23M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $15.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $35.28M 10-Q · filed 2026-08-12 | $70.05M derived: sum of 3 quarters · filed 2026-08-12 | $75.04M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $20.23M 10-Q · filed 2026-05-13 | $54.99M derived: sum of 2 quarters · filed 2026-05-13 | $59.99M derived: sum of 3 quarters · filed 2026-05-13 | $194.82M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $34.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $39.76M derived: sum of 2 quarters · filed 2026-03-19 | $174.59M derived: sum of 3 quarters · filed 2026-03-19 | $202.93M 10-K · filed 2026-03-19 |
| 2024-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $139.83M derived: sum of 2 quarters · filed 2025-11-13 | $168.16M 10-Q · filed 2025-11-13 | $184.75M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $134.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $163.17M 10-Q · filed 2025-08-13 | $179.75M derived: sum of 3 quarters · filed 2025-08-13 | $202.73M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $28.34M 10-Q · filed 2025-05-14 | $44.92M derived: sum of 2 quarters · filed 2025-05-14 | $67.90M derived: sum of 3 quarters · filed 2025-05-14 | $67.90M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $16.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $39.56M derived: sum of 2 quarters · filed 2025-03-27 | $39.56M derived: sum of 3 quarters · filed 2025-03-27 | $56.53M 10-K · filed 2025-03-27 |
| 2023-09-30 | $22.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $22.98M derived: sum of 2 quarters · filed 2024-11-13 | $39.95M 10-Q · filed 2024-11-13 | $140.76M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $16.96M 10-Q · filed 2024-08-13 | $117.77M derived: sum of 3 quarters · filed 2024-08-13 | |
| 2023-03-31 | $16.96M 10-Q · filed 2024-05-14 | $117.77M derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $100.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $150.18M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $49.37M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |